Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.90 ▼ -0.02
(-0.86%)
MKT CAP: $3.9M • VOL: 28.8K
52W L $3 52W H $142
ROARABLE / RQD
D • 45/100
PIOTROSKI
1 / 9
LIMN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$3.0M | -$3.3M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$10.2M | -$3.5M |
| EBITDA (Normalized) | -$3.0M | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$10.0M | -$1.5M |
| Capital Expenditures (CapEx) | $13.1K | — |
| Free Cash Flow (FCF) | -$10.0M | -$1.5M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | — | — |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | -$9.8M | -$19.3M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LIMN.